A Master Protocol study to investigate biomarker-guided novel anticancer agent(s) as monotherapy or combination therapy in participants with advanced/recurrent ovarian cancer

Trial Identifier: D9724C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: September 2025
Primary Completion Date: March 2029
Study Completion Date: March 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ES Barcelona, ES, 08028
ES Barcelona, ES, 8035
ES Valencia, ES, 46026
ES Valencia, ES, 46010
IT Milan, IT, 20159
IT Milano, IT, 20162
IT Milano, IT, 20132
IT Milano, IT, 20141
IT Monza, IT, 20900
IT Ravenna, IT, 48100
IT Rome, IT, 00168
KR Goyang, KR, 410-769
KR Seoul, KR, 135-720
KR Seoul, KR, 03080
KR Seoul, KR, 08308
US, CA Fullerton, CA, US, 92835
US, NM Albuquerque, NM, US, 87109
US, OK Oklahoma City, OK, US, 73104
US, SD Sioux Falls, SD, US, 57105
US, WA Seattle, WA, US, 98109